Episode 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Cohen, MD. [LISTEN TIME: 20 minutes]
Sharon Cohen, MD
Episode 122 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
In this episode, "RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease," Sharon Cohen, MD, a behavioral neurologist, sat down to discuss positive data from an ongoing phase 1 study of mivelsiran (Alnylam Pharmaceuticals), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer disease (AD). Cohen, who also serves as the medical director of the Toronto Memory Program at the University of Toronto, discussed the potential of RNA therapeutics for treating AD, the unique mechanism of action of mivelsiran, and some of the early promising safety, efficacy, and pharmacokinetic data observed in the phase 1 trial. In addition, Cohen touched upon the idea of how RNA therapeutics could be used in combination with previously approved novel treatments and the benefits mivelsiran brings with no observed amyloid-related imaging abnormalities. Furthermore, the discussion covered some of the potential of this investigational agent, what to expect in the multi-dose part B of the study, and an additional phase 2 study in cerebral amyloid angiopathy.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- FDA Clears Indapta Therapeutics’ IND for Cell Therapy IDP-023 in Progressive Multiple Sclerosis
- Muscle-Targeting Therapy Apitegromab Effective in Spinal Muscular Atrophy Over 4 Year Period
- FDA Approves Medtronic’s Deep Brain Stimulation Technology for Asleep Capabilities
EPISODE BREAKDOWN
- 1:15 – Mechanism of action of mivelsiran and how it can be potentially beneficial in AD
- 4:15 – Growing knowledge of RNA therapeutics and their impact on neurologic conditions
- 7:00 – Neurology News Minute
- 10:10 – Phase 1 study data, including efficacy, safety, biomarker, and pharmacokinetic results
- 19:20 – How mivelsiran fits with other approved therapies for AD; future goals and directions of the drug
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below:
